Cytomed Therapeutics refutes ‘misleading’ claims, reaffirms clinical progress

CytoMed Therapeutics (GDTC) issued a statement to address recent statements containing “inaccurate and misleading” claims regarding the Company’s research programs, clinical progress, and operations.The company said, ” CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company’s scientific focus, development status, and regulatory standing. Please refer to recent announcements by the Company on our progress. CytoMed’s research is focu ...